Werewolf Therapeutics, Inc. (HOWL) Form 8-K — Aug 21, 2026
On August 21, 2026, Werewolf Therapeutics (HOWL) signed a definitive merger agreement under which Wave Atlantis Merger Sub will merge into Ambros Therapeutics, leaving Ambros as a wholly owned Werewolf subsidiary; the combined company will be renamed Ambros Therapeutics and both boards unanimously approved the deal. Concurrently, Werewolf agreed to a $150.0 million PIPE financing with institutional investors closing immediately before the merger, with at least $100.0 million of net proceeds required as a closing condition; Leerink Partners, Piper Sandler, Cantor Fitzgerald, Wells Fargo Securities and LifeSci Capital are acting as placement agents.
Key figures
- Gross Proceeds
- 150000000
- Cvr terms
- one non-transferable CVR per Werewolf share tied to proceeds from legacy WTX-124 and WTX-330 INDUKINE programs
- Lockup period
- 180 days post-effective time
- Ambros equity value
- $500.0 million
- Ambros termination fee
- $20.0 million
- Werewolf target net cash
- $30.0 million
- Werewolf termination fee
- $1.9 million
- Werewolf valuation floor
- $5.5 million
- Werewolf implied valuation
- $47.5 million
- Ambros holders pro forma ownership
- approximately 71.7%
- Pipe investors pro forma ownership
- approximately 21.5%
- Werewolf holders pro forma ownership
- approximately 6.8%
- Minimum pipe proceeds closing condition
- $100.0 million
Price after filing
Close on the filing date to close N calendar days later (from $0.87). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.